RecruitingPhase 2NCT07641179

A Study to Evaluate MAR002 for Acromegaly

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR002 in Participants With Acromegaly (TROUGH-2)

Sponsor

Marea Therapeutics

Enrollment

72 participants

Start Date

Jul 23, 2026

Study Type

INTERVENTIONAL

Conditions

Acromegaly

Summary

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MAR002 and a drug called Placebo for people with acromegaly. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.